Exactly one year after President Donald Trump announced his sweeping tariff programme dubbed “Liberation Day,” new trade data and fresh policy moves underscored an era of continuing disruption and uncertainty for global markets. U.S. trade figures released Thursday showed the goods and services deficit widened in February after a jump in imports offset strong exports, while the administration used the anniversary to unveil new duties on drugs and metals.
“Liberation Day” has set off 12 months of volatile policy shifts that have yet to settle. The White House’s tariff drive prompted investors and multinational companies to reassess exposure to U.S. assets, upended established supply-chain arrangements and triggered legal fights that reached the Supreme Court. In a significant development in February, the court struck down most of the administration’s duties, a move that compounded corporate confusion even as Washington continued to deploy trade measures through other routes.
To mark the one-year point, the administration announced targeted tariffs on pharmaceuticals and a range of metals, reviving fresh debate over protectionism and the costs to consumers and trading partners. Industry groups and foreign governments have pushed back. Swiss pharmaceutical associations warned that steep duties on branded medicines would disrupt global production and research networks and urged government intervention to shield critical medical supplies, industry representatives said this week.
Market analysts and commentators remain divided over the longer-term effects of the tariff campaign. While some critics had warned of an economic collapse from abrupt trade barriers, that scenario has not materialised. Instead, one conservative commentator argued the episode has produced what he called a “retroactive tolerance for robust protectionism,” signaling a potential shift in political economy where stronger trade measures are increasingly acceptable across the political spectrum.
Companies have had to navigate a patchwork of shifting rules, court rulings and administrative actions. That uncertainty has influenced corporate investment decisions and supply-chain strategies, with some manufacturers — notably in the automotive sector — accelerating plans to produce more in the United States in response to trade pressures and incentives, while others press for exemptions or adjustments to avoid crippling cost increases.
With the Supreme Court having curtailed much of the original tariff architecture and the administration continuing to add targeted duties, the coming months are likely to see a mix of litigation, diplomatic negotiations and ad-hoc policy moves. For governments and industries reliant on integrated cross-border production, the priority will be securing carve-outs and clarifying rules of origin, while investors watch whether the recent rise in imports and the broader policy oscillation presage a sustained change in global trade patterns.